Use of biosynthetic growth hormone in children of short stature. Investigation of cardiovascular effects
DEC-NET Serial number GB297
Published online22/07/2004 17.29.00
Last updated09/08/2005 11.40.02
This trial has been approved by an ethics committee
Current trial statusComplete(closed to recruitment of participants: follow-up complete)
Major Disease
(ICD9 class)		DWARFISM NOT ELSEWHERE CLASSIFIED
Experimental drug
Somatropin
GenderBoth
Age (range)< 10 years

Eligibility criteria
Inclusion criteria
Normal growth hormone secretion
Exclusion criteria
Growth hormone deficiency or skeletal dysplasia

Trial design/methodology
Phase4
Kind of studyEfficacy
Safety
DesignControlled
Blinded
Single blind
Purpose of study
What cardiovascular effects are seen in children of short stature treated with biosynthetic growth hormone?
Primary outcomes
Final Height
Secondary outcomes
Cardiac Function
Summary of study design, objectives, and ongoing research findings
Clinical Trial without Randomisation. What cardiovascular effects are seen in children of short stature treated with biosynthetic growth hormone?
Principal investigator
NameDr PC Hindmarsh
InstitutionCobbold Laboratories, The Middlesex Hospital
Postal addressDepartment of Paediatrics, Cobbold Laboratories, 7th Floor, The Middlesex Hospital, Mortimer Street, London, W1N 8AA
CityLondon
CountryUNITED KINGDOM
Phone020 7380 9450
Fax020 7636 9941
E-mailp.hindmarsh@ucl.ac.uk


Sponsor name
Children Nationwide Research Fund (Charity)

ISRCTN  EudraCT